The COVID-19 has been a worldwide pandemic and it wants for research associated to impact on individuals’s demand for insurance throughout the pandemic which is a vital solution to switch threat. However, there’s a lack of analysis linking COVID-19 and other people’s demand for insurance. The goal of this paper is to analyze the impact of COVID-19 pandemic on issuance demand, utilizing knowledge overlaying 241 cities on confirmed COVID-19 circumstances and insurance firm income in China.
The empirical outcomes present that extra confirmed COVID-19 circumstances are related to better per capita insurance income and the outcomes are strong when contemplating endogeneity concern.
Economically, the per capita insurance income will increase by 0.896 Yuan for every extra confirmed case. In phrases of insurance kind, the best elevated insurance income is for all times insurance, adopted by well being insurance. We additional think about the heterogeneity of areas and discover that the impact of COVID-19 on insurance income solely exists in areas with worse medical therapy circumstances or larger medical burden.
Acquired ABC-transporter overexpression in most cancers cells: transcriptional induction or Darwinian choice?
Acquired multidrug resistance (MDR) in tumor illnesses has repeatedly been related to overexpression of ATP-binding cassette transporters (ABC-transporters) corresponding to P-glycoprotein. Both in vitro and in vivo knowledge counsel that these efflux transporters may cause MDR, albeit its precise relevance for medical chemotherapy unresponsiveness stays unsure. The overexpression can experimentally be achieved by publicity of tumor cells to cytotoxic medicine.
For simplification, the drug-mediated transporter overexpression will be attributed to 2 reverse mechanisms: First, elevated transcription of ABC-transporter genes mediated by nuclear receptors sensing the respective compound. Second, Darwinian choice of sub-clones intrinsically overexpressing drug transporters being succesful of extruding the respective drug. To date, there isn’t a particular knowledge indicating which mechanism actually applies or whether or not there are circumstances selling both mode of motion.
This evaluation summarizes experimental proof for each theories, suggests an algorithm discriminating between these two modes, and at last factors out future experimental approaches of analysis to reply this primary query in most cancers pharmacology.
Facilitating Growth Mixture Model Convergence in Preventive Interventions
Growth combination fashions (GMMs) are utilized to intervention research with repeated measures to discover heterogeneity in the intervention impact. However, conventional GMMs are recognized to be troublesome to estimate, particularly at pattern sizes frequent in single-center interventions. Common methods to coerce GMMs to converge contain put up hoc changes to the mannequin, notably constraining covariance parameters to equality throughout courses.
Methodological research have proven that though convergence is improved with put up hoc changes, they embed extra tenuous assumptions into the mannequin that may adversely impact key points of the mannequin corresponding to quantity of courses extracted and the estimated progress trajectories in every class. To facilitate convergence with out put up hoc changes, this paper critiques the current literature on covariance sample combination fashions, which method GMMs from a marginal modeling custom fairly than the random impact modeling custom utilized by conventional GMMs.
We talk about how the marginal modeling custom can keep away from complexities in estimation encountered by GMMs that function random results, and we use knowledge from a life-style intervention for rising insulin sensitivity (a threat issue for kind 2 diabetes) amongst 90 Latino adolescents with weight problems to reveal our level. Specifically, GMMs that includes random effects-even with put up hoc adjustments-fail to converge as a result of estimation errors, whereas covariance sample combination fashions following the marginal mannequin custom encounter no points with estimation whereas sustaining the capability to reply all the analysis questions.
Effect of storage time on the urine protein: creatinine ratio in alkaline ovine urine
The urine protein:creatinine (UPC) ratio is taken into account the reference methodology to evaluate proteinuria. Its diagnostic worth in ovine drugs wants additional elucidation. In inhabitants monitoring and/or for analysis functions, it’s handy to gather many samples concurrently and retailer them for later evaluation. However, analyte stability knowledge are required to make sure dependable outcomes. We used 15 of 90 urine samples collected from sheep to evaluate the impact of storage time on the UPC ratio. After centrifugation, the supernatant of every pattern was divided into 6 aliquots.
Urine protein and creatinine concentrations had been decided instantly in a single aliquot utilizing the pyrogallol purple and a modified Jaffè methodology, respectively. The different aliquots had been saved at -18°C. Based on the absence of energetic sediment, alkaline urine pH, and UPC ratio ≥ 0.2, we included 15 samples in our research.
The UPC ratio was decided in the saved aliquots 2, 7, 14, 21, and 60 d after assortment. The knowledge had been analyzed with univariate ANOVA. No important distinction was noticed in the urinary concentrations of protein, creatinine, and the UPC ratio (0.8 ± 0.84 in typical models and 0.09 ± 0.095 in SI models) amongst totally different instances (p > 0.05). The UPC ratio remained steady for two mo in ovine urine samples saved at -18°C.
Multimodal Disentangled Variational Autoencoder with Game Theoretic Interpretability for Glioma grading
Effective fusion of multimodal magnetic resonance imaging (MRI) is of nice significance to spice up the accuracy of glioma grading because of the complementary info supplied by totally different imaging modalities. However, how you can extract the frequent and distinctive info from MRI to realize complementarity remains to be an open downside in info fusion analysis. In this research, we suggest a deep neural community mannequin termed as multimodal disentangled variational autoencoder (MMD-VAE) for glioma grading based mostly on radiomics options extracted from preoperative multimodal MRI photographs.
Specifically, the radiomics options are quantized and extracted from the area of curiosity for every modality. Then, the latent representations of variational autoencoder for these options are disentangled into frequent and distinctive representations to acquire the shared and complementary knowledge amongst modalities. Afterward, cross-modality reconstruction loss and common-distinctive loss are designed to make sure the effectiveness of the disentangled representations.
Finally, the disentangled frequent and distinctive representations are fused to foretell the glioma grades, and SHapley Additive exPlanations (SHAP) is adopted to quantitatively interpret and analyze the contribution of the essential options to grading.
FGF21 Polyclonal Antibody |
BT-AP09138-100ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
100ul |
Ask for price |
|
Description: Theis gene encodes a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. This protein is a secreted endocrine factor that functions as a major metabolic regulator. The encoded protein stimulates the uptake of glucose in adipose tissue. |
FGF21 Polyclonal Antibody |
BT-AP09138-20ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
20ul |
Ask for price |
|
Description: Theis gene encodes a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. This protein is a secreted endocrine factor that functions as a major metabolic regulator. The encoded protein stimulates the uptake of glucose in adipose tissue. |
FGF21 Polyclonal Antibody |
BT-AP09138-50ul |
Jiaxing Korain Biotech Ltd (BT Labs) |
50ul |
Ask for price |
|
Description: Theis gene encodes a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes. This protein is a secreted endocrine factor that functions as a major metabolic regulator. The encoded protein stimulates the uptake of glucose in adipose tissue. |
FGF21 Polyclonal Antibody |
E-AB-15031-120uL |
Elabscience Biotech |
120uL |
EUR 240 |
|
Description: Unconjugated |
FGF21 Polyclonal Antibody |
E-AB-15031-200uL |
Elabscience Biotech |
200uL |
EUR 399 |
|
Description: Unconjugated |
FGF21 Polyclonal Antibody |
E-AB-15031-20uL |
Elabscience Biotech |
20uL |
EUR 73 |
|
Description: Unconjugated |
FGF21 Polyclonal Antibody |
E-AB-15031-60uL |
Elabscience Biotech |
60uL |
EUR 143 |
|
Description: Unconjugated |
FGF21 Polyclonal Antibody |
E11-200199 |
EnoGene |
100ug/100ul |
EUR 225 |
Description: Available in various conjugation types. |
FGF21 Polyclonal Antibody |
JOT-AP09138-100ul |
Jotbody |
100ul |
EUR 220 |
|
FGF21 Polyclonal Antibody |
JOT-AP09138-50ul |
Jotbody |
50ul |
EUR 144 |
|
FGF21 Polyclonal Antibody |
E44H07806 |
EnoGene |
100ul |
EUR 255 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
FGF21 Polyclonal Antibody |
E910368 |
EnoGene |
100ul |
EUR 225 |
Description: Available in various conjugation types. |
FGF21 Polyclonal Antibody |
MBS2547657-006mL |
MyBiosource |
0.06mL |
EUR 180 |
FGF21 Polyclonal Antibody |
MBS2547657-012mL |
MyBiosource |
0.12mL |
EUR 260 |
FGF21 Polyclonal Antibody |
MBS2547657-02mL |
MyBiosource |
0.2mL |
EUR 405 |
FGF21 Polyclonal Antibody |
MBS2547657-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1725 |
FGF21 Polyclonal Antibody |
MBS2529968-002mL |
MyBiosource |
0.02mL |
EUR 135 |
FGF21 Polyclonal Antibody |
MBS2529968-006mL |
MyBiosource |
0.06mL |
EUR 190 |
FGF21 Polyclonal Antibody |
MBS2529968-012mL |
MyBiosource |
0.12mL |
EUR 265 |
FGF21 Polyclonal Antibody |
MBS2529968-02mL |
MyBiosource |
0.2mL |
EUR 415 |
FGF21 Polyclonal Antibody |
MBS2529968-5x02mL |
MyBiosource |
5x0.2mL |
EUR 1835 |
FGF21 Polyclonal Antibody |
MBS2525073-002mL |
MyBiosource |
0.02mL |
EUR 140 |
FGF21 Polyclonal Antibody |
MBS2525073-006mL |
MyBiosource |
0.06mL |
EUR 180 |
FGF21 Polyclonal Antibody |
MBS2525073-012mL |
MyBiosource |
0.12mL |
EUR 260 |
FGF21 Polyclonal Antibody |
MBS2525073-02mL |
MyBiosource |
0.2mL |
EUR 405 |
FGF21 Polyclonal Antibody |
MBS9130877-002mL |
MyBiosource |
0.02mL |
EUR 200 |
FGF21 Polyclonal Antibody |
MBS9130877-005mL |
MyBiosource |
0.05mL |
EUR 255 |
FGF21 Polyclonal Antibody |
MBS9130877-01mL |
MyBiosource |
0.1mL |
EUR 345 |
FGF21 Polyclonal Antibody |
MBS9130877-02mL |
MyBiosource |
0.2mL |
EUR 545 |
FGF21 Polyclonal Antibody |
MBS9130877-5x02mL |
MyBiosource |
5x0.2mL |
EUR 2265 |
FGF21 Polyclonal Antibody |
MBS8529536-01mg |
MyBiosource |
0.1mg |
EUR 305 |
FGF21 Polyclonal Antibody |
MBS8529536-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 465 |
FGF21 Polyclonal Antibody |
MBS8529536-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 465 |
FGF21 Polyclonal Antibody |
MBS8529536-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 465 |
FGF21 Polyclonal Antibody |
MBS8529536-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 465 |
FGF21 Polyclonal Antibody |
MBS8566451-01mL |
MyBiosource |
0.1mL |
EUR 305 |
FGF21 Polyclonal Antibody |
MBS8566451-01mLAF405L |
MyBiosource |
0.1mL(AF405L) |
EUR 565 |
FGF21 Polyclonal Antibody |
MBS8566451-01mLAF405S |
MyBiosource |
0.1mL(AF405S) |
EUR 565 |
FGF21 Polyclonal Antibody |
MBS8566451-01mLAF610 |
MyBiosource |
0.1mL(AF610) |
EUR 565 |
FGF21 Polyclonal Antibody |
MBS8566451-01mLAF635 |
MyBiosource |
0.1mL(AF635) |
EUR 565 |
FGF21 Polyclonal Antibody |
RD78090A-120uL |
Reddot Biotech |
120μL |
EUR 360 |
|
Description: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The function of this growth factor has not yet been determined. |
FGF21 Polyclonal Antibody |
RD78090A-200uL |
Reddot Biotech |
200μL |
EUR 630 |
|
Description: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The function of this growth factor has not yet been determined. |
FGF21 Polyclonal Antibody |
RD78090A-20uL |
Reddot Biotech |
20μL |
EUR 109.5 |
|
Description: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The function of this growth factor has not yet been determined. |
FGF21 Polyclonal Antibody |
RD78090A-60uL |
Reddot Biotech |
60μL |
EUR 214.5 |
|
Description: The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. The function of this growth factor has not yet been determined. |
FGF21 Polyclonal Antibody |
UB-GEN-4940 |
UpingBio |
100 ul |
EUR 200 |
FGF21 Rabbit Polyclonal Antibody |
ES9145-100ul |
ELK Biotech |
100ul |
EUR 124 |
|
Description: WB, ELISA |
FGF21 Rabbit Polyclonal Antibody |
ES9145-50ul |
ELK Biotech |
50ul |
EUR 74 |
|
Description: WB, ELISA |
FGF21 Rabbit Polyclonal Antibody |
E10G08328 |
EnoGene |
100 μl |
EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
FGF21 Rabbit Polyclonal Antibody |
E10G01370 |
EnoGene |
100 μl |
EUR 275 |
Description: Biotin-Conjugated, FITC-Conjugated , AF350 Conjugated , AF405M-Conjugated ,AF488-Conjugated, AF514-Conjugated ,AF532-Conjugated, AF555-Conjugated ,AF568-Conjugated , HRP-Conjugated, AF405S-Conjugated, AF405L-Conjugated , AF546-Conjugated, AF594-Conjugated , AF610-Conjugated, AF635-Conjugated , AF647-Conjugated , AF680-Conjugated , AF700-Conjugated , AF750-Conjugated , AF790-Conjugated , APC-Conjugated , PE-Conjugated , Cy3-Conjugated , Cy5-Conjugated , Cy5.5-Conjugated , Cy7-Conjugated Antibody |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2003047-01mL |
MyBiosource |
0.1mL |
EUR 180 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2003047-02mL |
MyBiosource |
0.2mL |
EUR 225 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2003047-05mL |
MyBiosource |
0.5mL |
EUR 375 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2003047-1mL |
MyBiosource |
1mL |
EUR 455 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2003047-5mL |
MyBiosource |
5mL |
EUR 1250 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2112261-01mL |
MyBiosource |
0.1mL |
EUR 195 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2112261-02mL |
MyBiosource |
0.2mL |
EUR 240 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2112261-05mL |
MyBiosource |
0.5mL |
EUR 420 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2112261-1mL |
MyBiosource |
1mL |
EUR 510 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2112261-5mL |
MyBiosource |
5mL |
EUR 1415 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027461-01mL |
MyBiosource |
0.1mL |
EUR 150 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027461-02mL |
MyBiosource |
0.2mL |
EUR 175 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027461-05mL |
MyBiosource |
0.5mL |
EUR 275 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027461-1mL |
MyBiosource |
1mL |
EUR 320 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027461-5mL |
MyBiosource |
5mL |
EUR 865 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027908-01mL |
MyBiosource |
0.1mL |
EUR 180 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027908-02mL |
MyBiosource |
0.2mL |
EUR 225 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027908-05mL |
MyBiosource |
0.5mL |
EUR 380 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027908-1mL |
MyBiosource |
1mL |
EUR 465 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027908-5mL |
MyBiosource |
5mL |
EUR 1285 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2028129-01mL |
MyBiosource |
0.1mL |
EUR 175 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2028129-02mL |
MyBiosource |
0.2mL |
EUR 220 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2028129-05mL |
MyBiosource |
0.5mL |
EUR 365 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2028129-1mL |
MyBiosource |
1mL |
EUR 445 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2028129-5mL |
MyBiosource |
5mL |
EUR 1220 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027242-01mL |
MyBiosource |
0.1mL |
EUR 180 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027242-02mL |
MyBiosource |
0.2mL |
EUR 225 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027242-05mL |
MyBiosource |
0.5mL |
EUR 380 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027242-1mL |
MyBiosource |
1mL |
EUR 465 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2027242-5mL |
MyBiosource |
5mL |
EUR 1285 |
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
PAC918Hu01 |
Cloud-Clone |
100ul |
EUR 175 |
|
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
PAC918Mu01 |
Cloud-Clone |
100ul |
EUR 259 |
|
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
PAC918Mu02 |
Cloud-Clone |
100ul |
EUR 252 |
|
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
PAC918Ra01 |
Cloud-Clone |
100ul |
EUR 266 |
|
Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
PAC918Ra02 |
Cloud-Clone |
100ul |
EUR 266 |
|
FGF21 Polyclonal Antibody, HRP Conjugated |
A52639 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Fgf21 Polyclonal Antibody, HRP Conjugated |
A62587 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
FGF21 Polyclonal Antibody, FITC Conjugated |
A52638 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Fgf21 Polyclonal Antibody, FITC Conjugated |
A62588 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
FGF21 Polyclonal Antibody FITC Conjugated |
MBS9463342-01mL |
MyBiosource |
0.1mL |
EUR 595 |
FGF21 Polyclonal Antibody FITC Conjugated |
MBS9463342-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2525 |
FGF21 Polyclonal Antibody FITC Conjugated |
MBS9463376-01mL |
MyBiosource |
0.1mL |
EUR 595 |
FGF21 Polyclonal Antibody FITC Conjugated |
MBS9463376-5x01mL |
MyBiosource |
5x0.1mL |
EUR 2525 |
FGF21 Polyclonal Antibody, Biotin Conjugated |
A52637 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Fgf21 Polyclonal Antibody, Biotin Conjugated |
A62589 |
EpiGentek |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
Anti-Fibroblast Growth Factor 21 (FGF21) Polyclonal Antibody |
FAC918Hu01 |
Cloud-Clone |
50T |
EUR 220 |
|
Anti-Fibroblast Growth Factor 21 (FGF21) Polyclonal Antibody |
MBS2127083-02mL |
MyBiosource |
0.2mL |
EUR 165 |
Anti-Fibroblast Growth Factor 21 (FGF21) Polyclonal Antibody |
MBS2127083-5x02mL |
MyBiosource |
5x0.2mL |
EUR 740 |
FGF21 Rabbit anti-Human Polyclonal (N-Terminus) Antibody |
MBS2402084-005mL |
MyBiosource |
0.05mL |
EUR 615 |
FGF21 Rabbit anti-Human Polyclonal (N-Terminus) Antibody |
MBS2402084-5x005mL |
MyBiosource |
5x0.05mL |
EUR 2605 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118821-01mL |
MyBiosource |
0.1mL |
EUR 280 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118821-02mL |
MyBiosource |
0.2mL |
EUR 375 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118821-05mL |
MyBiosource |
0.5mL |
EUR 695 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118821-1mL |
MyBiosource |
1mL |
EUR 855 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118821-5mL |
MyBiosource |
5mL |
EUR 2460 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118822-01mL |
MyBiosource |
0.1mL |
EUR 305 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118822-02mL |
MyBiosource |
0.2mL |
EUR 420 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118822-05mL |
MyBiosource |
0.5mL |
EUR 780 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118822-1mL |
MyBiosource |
1mL |
EUR 965 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118822-5mL |
MyBiosource |
5mL |
EUR 2765 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118823-01mL |
MyBiosource |
0.1mL |
EUR 285 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118823-02mL |
MyBiosource |
0.2mL |
EUR 380 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118823-05mL |
MyBiosource |
0.5mL |
EUR 710 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118823-1mL |
MyBiosource |
1mL |
EUR 875 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2118823-5mL |
MyBiosource |
5mL |
EUR 2525 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068968-01mL |
MyBiosource |
0.1mL |
EUR 220 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068968-02mL |
MyBiosource |
0.2mL |
EUR 275 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068968-05mL |
MyBiosource |
0.5mL |
EUR 485 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068968-1mL |
MyBiosource |
1mL |
EUR 595 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068968-5mL |
MyBiosource |
5mL |
EUR 1675 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068974-01mL |
MyBiosource |
0.1mL |
EUR 275 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068974-02mL |
MyBiosource |
0.2mL |
EUR 365 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068974-05mL |
MyBiosource |
0.5mL |
EUR 675 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068974-1mL |
MyBiosource |
1mL |
EUR 835 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068974-5mL |
MyBiosource |
5mL |
EUR 2395 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068980-01mL |
MyBiosource |
0.1mL |
EUR 285 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068980-02mL |
MyBiosource |
0.2mL |
EUR 380 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068980-05mL |
MyBiosource |
0.5mL |
EUR 710 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068980-1mL |
MyBiosource |
1mL |
EUR 875 |
PE-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2068980-5mL |
MyBiosource |
5mL |
EUR 2525 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120165-01mL |
MyBiosource |
0.1mL |
EUR 280 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120165-02mL |
MyBiosource |
0.2mL |
EUR 375 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120165-05mL |
MyBiosource |
0.5mL |
EUR 695 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120165-1mL |
MyBiosource |
1mL |
EUR 855 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120165-5mL |
MyBiosource |
5mL |
EUR 2460 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120166-01mL |
MyBiosource |
0.1mL |
EUR 305 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120166-02mL |
MyBiosource |
0.2mL |
EUR 420 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120166-05mL |
MyBiosource |
0.5mL |
EUR 780 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120166-1mL |
MyBiosource |
1mL |
EUR 965 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120166-5mL |
MyBiosource |
5mL |
EUR 2765 |
APC-Linked Polyclonal Antibody to Fibroblast Growth Factor 21 (FGF21) |
MBS2120167-01mL |
MyBiosource |
0.1mL |
EUR 285 |
Experimental outcomes on two benchmark knowledgeunits reveal that the proposed MMD-VAE mannequin achieves encouraging predictive efficiency (AUC:0.9939) on a public knowledgeset, and good generalization efficiency (AUC:0.9611) on a cross-institutional personal knowledgeset. These quantitative outcomes and interpretations could assist radiologists perceive gliomas higher and make higher therapy selections for bettering medical outcomes.